GLP-1 vs Dual-Agonist Medicines

Definitions

• GLP-1 receptor agonist. Semaglutide is the example read here. Its label describes a GLP-1 analogue with 94% sequence homology to human GLP-1 that binds and activates the GLP-1 receptor. [1]
• Dual GIP/GLP-1 receptor agonist. The tirzepatide label says it selectively binds and activates both the GIP and GLP-1 receptors, and that it contains a C20 fatty diacid that enables albumin binding and prolongs half-life. [2]

GLP-1 and GIP are both gut hormones released after eating. For the biology, see GLP-1 and GIP biology.

What the labels say about how they act

Semaglutide's label says GLP-1 is a physiological regulator of appetite and caloric intake and that its receptor is present in brain areas involved in appetite. [1] Tirzepatide's label says nonclinical studies suggest adding GIP may further contribute to the regulation of food intake. [2] "May" and "suggest" are the label's words: the added contribution of the second target is described as a possibility from nonclinical work, not a proven mechanism in people.

Comparing the medicines

What head-to-head trials show

Two trials funded by the maker of tirzepatide compared it with semaglutide. In type 2 diabetes (1,879 adults, 40 weeks, open-label), tirzepatide lowered HbA1c and weight more. [5] In obesity without diabetes (751 adults, 72 weeks, open-label), average weight change was -20.2% with tirzepatide and -13.7% with semaglutide. [6] Limits: sponsor funding, open-label design, and surrogate outcomes. These trials compare two specific drugs, so they cannot be read as proof that "dual beats single" in general; the extra target and the drug's other design features are not separated.

Other multi-target compounds

Health Canada lists retatrutide among examples of unauthorized injectable peptide drugs it has seized, alongside many other compounds. [7] Status of other multi-target compounds elsewhere was not reviewed for this page: Proper evidence not found in the sources read, so nothing is claimed. A product sold online with "dual" or "triple" in the name is not thereby approved. See approved, investigational and unapproved peptides.

Outcomes beyond weight and blood sugar

Cardiovascular, kidney, liver and sleep-apnea indications differ by brand and are set by each label, not by whether a drug is single or dual. For example, Wegovy lists cardiovascular risk reduction and MASH, while Zepbound lists sleep apnea. [1][2] See incretin-based medicines: clinical outcomes.

No universal winner

Both categories are prescription medicines with monitoring and safety information. Do not start, stop or switch based on a category label; talk with a prescriber. For the direct drug comparison, see semaglutide vs tirzepatide.